Intravesical bacillus Calmette-Guérin is the current first-line treatment for high-grade nonmuscle-invasive bladder cancer; however, a substantial proportion of patients are unresponsive to bacillus Calmette-Guérin treatment. While cystectomy...
Herein, we examined the use of BCG vaccine treatment in patients with NMIBC and the risk of death and dementia. To our knowledge, we present the largest-to-date population health study of intravesical BCG vaccine for bladder cancer and ADRD, using electronic health records from patients ...
Advanced Bladder Cancer For patients with advanced disease, platinum-basedcombination chemotherapyhas been the first-line treatment for decades, with cisplatin-based treatments yielding a better overall survival than carboplatin-based combinations (12-15 months vs. 9 months).62,63However most patients pr...
(aimed mainly at infants and children without previous exposure to mycobacteria); prevention of disease (targeting individuals with TB infection to prevent progression to TB disease); and prevention of recurrence (focusing on individuals after completion of TB treatment to prevent reinfection or ...
37,38 The immunity of prevention and treatment are different; BCG might function as an effective preventive measure but not as a treatment for lung cancer. The BCG vaccine was not associated with a decreased rate of bladder cancer in this study (HR, 1.34; 95% CI, 0.22-8.03). Strengths ...
Treatment with TAR-200 displayed a high complete response rate in Bacillus Calmette-Guérin-unresponsive high-risk non-muscle-invasive bladder cancer. Joseph Jacob, MD TAR-200, the novel targeted gemcitabine delivery system, delivered rapid and durable responses in patients with Bacillus Calmette-Guérin...
These studies may potentially provide a better understanding of how BCG and mitomycin work in NMIBC, or identify biomarkers that are able to better predict success of intravesical treatment or overall prognosis.Abbreviations ANZUP: Australian and New Zealand Urogenital and Prostate Cancer Trials Group ...
The all-cause mortality rate was 3.5% at 1 year, and 16.5% at 2 years. Neither bladder cancer nor the treatments were the cause of any of the deaths. Conclusions: Sequential intravesical gemcitabine and docetaxel is an effective treatment for BCG nave NIMBC. Treatments are generally well ...
n a phase 2 study of patients with BCG-unresponsive non–muscle invasive bladder cancer, treatment with recombinant pox-viral vector vaccine Panvac plus bacillus Calmette-Guérin did not significantly improve clinical outcomes. In a phase 2 study of patients with BCG-unresponsive non–mu...
However, there is currently no ability at the time of initial diagnosis to identify which of these patients will respond to standard-of-care treatment, intravesical administration of Bacillus Calmette-Guerin (BCG). Thus, Tis bladder cancer patients are often treated subjectively using a "one size ...